The use of Mirena in the treatment of menorrhagia in Basra


  • Zinab abd Ali
  • Sajda ALrubia Assistant Prof. Basra Medical College


Objective : To evaluate the efficacy and safety of mirena in the long term treatment of heavy menstrual blood loss in women with benign causes in Basra. Maternal and Methods : A prospective observational study, non comparative study, conducted at Basra maternity and child hospital over a period of four years from 1st of Jan.2009 to the first of Jan. 2013. It consist of 112 women. All have heavy menstrual bleeding for benign causes having no contraindication for the device all women were followed up at 3 months, 6 months and 12 months. Result : Majority of women had menstrual spotting after 3-6 months, followed by infrequent menstruation, scanty period or Amenorrhaea, (71.4%) continued to use mirena beyond 1 years. while the discontinuation rate was (29.6%). Haemoglobin and serum ferritin and PCV level increased over 12 months of use, It was found that the most common side effect were bleeding disturbance (16%) no pregnancies occur during the study period , so mirena is a safe and effective option for women with menorrhagia in perimenopasual period.


Edlun M, Magnuson C, Von Scool t3 B. Quality of life, a Swedish survey of 2200 women. Dysfunctional uterine bleeding London: Royal society of Medicine, 1994.

Cole SK, Billewicz WZ, Sources of variation in menstrual blood loss. J. Obst. Gynae. Br. Common W. 1971; 78(10): 933-9.

Scholten PC, Janssen CA, Heinitz APM. A simple visual assessment technique to Discriminate between menorrhagia and normal menstrual blood loss. Obst. Gynaecol. 1995; 85(6): 977-982.

Prior JC. Perimenapause. The complex endocrinology of the menopausal transition. Endocr. Rev 1998; 397-248.

Lefebree G Bounchord C. Heywood M. Clinical practice guidelines for hysterectomy J Soc. Obst. Gynaecol. Can. 1966;18 (7): 677-87.

Luukkainen, T, Toivonen J. LNG. IUD as a method of contraception with therapeutic prosperities. Contraception 1995, Nov; 52(5) : 269-76.

Munro MG. Abnormal uterine bleeding in the reproductive years. Part II. J AM. Assoc. Gynaecol. Laparoscopy 2000; 7: 17-35.

Edlund M, Anderson K. Reduction of menstrual blood loss in women suffering from idiopatic menorrhagia with antifibrinolytic Br. J. Obstet. Gynaecol. 1995; 102: 913-7.

Perston JT, Comeron IT et al comparative study of tranexamic acid and norethisterone in the treatment of menorrhagia. Br. J. Obstet. Gynaecol. 1995; 102: 401-6.

Radesic B, shorma A. LNG. IUS for treating menstrual disorders : a patient satisfaction questionnaire. Aust NZJ. Obstet. Gynaecol. 2004; 44(3): 247-51.

Milson I. The levonorgestred releasing intrauterine system as an alternative to hysterectomy in perimenapausl women. Contraception 2007; 75: (6): 125-4.

Endrikal J. Vito G, Muysers C, The LNG. IUS provides a reliable. Longterm treatment option for women with idiopathic menorrhagia. Arch. Gynaecol. Obstet. 2012; 285: 117-21.

Munro MG. Critchley HO, Frasoris FIGO working group on menstruate disorders. FIGO classification system for causes of abnormal uterine bleeding in non gravid women of reproductive age. Int. J. Gynaeco. Obstet. 2011; 113: 3-13.

Costales A, Jensen J, Nelson A. A USA mult. Center. Open-label trial related with LNG. IUS. Clinical and device related experience. Contraception 2002; 74: 178-183.